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Background: The need for high-quality evidence that is applicable in real-world, routine settings continues to
increase. Pragmatic trials are designed to evaluate the effectiveness of interventions in real-world settings, whereas
explanatory trials aim to test whether an intervention works under optimal situations. There is a continuum
between explanatory and pragmatic trials. Most trials have aspects of both, making it challenging to label and
categorize a trial and to evaluate its potential for translation into practice.
Methods: We summarize our experience applying the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS)
combined with external validity items based on the Reach, Effectiveness, Adoption, Implementation, and Maintenance
(RE-AIM) framework to three studies to provide a more robust and comprehensive assessment of trial characteristics
related to translation of research. We summarize lessons learned using domains from the combined frameworks for use
in study planning, evaluating specific studies, and reviewing the literature and make recommendations for future use.
Results: A variety of coders can be trained to use the PRECIS and RE-AIM domains. These domains can also be used for
diverse purposes, content areas, and study types, but are not without challenges. Both PRECIS and RE-AIM domains
required modification in two of the three studies to evaluate and rate domains specific to study type. Lessons learned
involved: dedicating enough time for training activities related to the domains; use of reviewers with a range of
familiarity with specific study protocols; how to best adapt ratings that reflect complex study designs; and differences
of opinion regarding the value of creating a composite score for these criteria.
Conclusions: Combining both frameworks can specifically help identify where and how a study is and is not
pragmatic. Using both PRECIS and RE-AIM allows for standard reporting of key study characteristics related to
pragmatism and translation. Such measures should be used more consistently to help plan more pragmatic studies,
evaluate progress, increase transparency of reporting, and integrate literature to facilitate translation of research into
practice and policy.
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Over the last several years, there has been a substantial
movement toward practical, pragmatic implementation
research that will translate into usable health-related
policies, programs and practices [1–4]. Pragmatic re-
search is conducted internationally in wide ranging set-
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search can be traced to a seminal paper by Schwartz and
Lellouch [12] wherein they define explanatory research
as conducted under optimal circumstances to determine
the ‘efficacy’ of an intervention while pragmatic research
tests an intervention under usual conditions. This distinc-
tion is important because trials are frequently designed as
explanatory investigations, when the researchers’ intent is
actually to answer the pragmatic question of effectiveness
under usual or differing conditions. Inasmuch as trials are
inadequately formulated for the type of research question
asked, research outcomes are compromised and effort
wasted [12]. The importance of pragmatic research has
been given a major boost by the development of criteria
and evaluation tools intended to increase transparency of
research and results reporting and provide a means for
practitioners and policy makers to assess local applicability
of trial findings [13–15].
The ‘Pragmatic-Explanatory Continuum Indicator Sum-
mary’ or PRECIS framework was developed to assist trial
designers to assess where a trial is positioned along the
pragmatic to explanatory continuum [16]. The main pur-
pose of PRECIS is to determine the degree to which study
design decisions align with the trial’s stated purpose, and
thus was originally intended to be used at the design stage.
The tool is comprised of 10 domains: participant eligibility
criteria, experimental intervention flexibility, experi-
mental intervention practitioner expertise, comparison
intervention, comparison intervention practitioner expert-
ise, follow-up intensity, primary trial outcome, participant
compliance with prescribed intervention, practitioner ad-
herence to study protocol, and analysis of primary out-
come (see Table 1).
The original intent of the PRECIS framework was to
inform trial designs by providing a visual display in the
form of a hub and spoke diagram, where each of the 10
domains are represented by a line depicting the pragmatic-
explanatory continuum. No numerical anchors were ori-
ginally used. The endpoint closest to the hub represented a
more explanatory study, whereas the endpoint furthest
away from the hub represented a more pragmatic study
[16]. However, modifications have been proposed and
tested in variety of ways in an attempt to expand its utility
to evaluate studies post completion, including use in sys-
tematic reviews [17–21]. Modifications have included
quantifying the pragmatic-explanatory nature of a study by
using numeric rating systems, where each domain is scored
on a Likert-type scale. The original scale ranged from 0 to
4 where 0 represented an extremely pragmatic study and 4
was extremely explanatory. Over time the range most com-
monly used has been 1 to 5 (scales of 0 to 4 and 1 to 20
have also been used) [22]. Regardless of which scale is used,
all have transposed the endpoints so the smaller number
represents an extremely explanatory study and the largernumber represents an extremely pragmatic study. Another
modification was made to accommodate evaluating sys-
tematic reviews. Each study in a systematic review is scored
individually on each of the 10 original PRECIS domains
[20]. After the individual scoring, a 10-domain average for
each individual trial can be calculated, as well as a single
domain average across all trials included in the review and
an overall combined average for the entire systematic
review. Regardless of which version was used, all studies
concluded that PRECIS was useful in designing trials
and assessing the level of pragmatism of a trial or a body
of evidence. However, PRECIS does not include do-
mains to evaluate generalizability and applicability of a
pragmatic trial to a specific context. Thus, additional
domains are required.
The RE-AIM framework, which is an acronym for reach,
effectiveness, adoption, implementation, and maintenance,
was created out of the need for improved reporting on key
issues related to robustness, translatability, and public
health impact of health research [23,24]. RE-AIM was de-
veloped as a response to trends toward research con-
ducted under optimal efficacy conditions instead of in
real-world, complex settings [25] and is intended to be
used at all stages of research from planning through evalu-
ation and reporting, and across different types of research
(e.g., effectiveness, implementation, and dissemination
trials) [26]. RE-AIM domains address issues focused on
setting and participant representativeness, setting/site en-
gagement with intervention, intervention adaptation dur-
ing the study, program sustainability, and monetary/
resource costs of an intervention. Over the past 14 years,
RE-AIM has been applied to a wide range of conditions
and study settings and has evolved to include additional
items necessary for translation of research findings, such
as use of qualitative methods and assessment of unantici-
pated consequences, both negative and positive (e.g.
generalization effects). These domains address pragmatic
and external validity issues not included within the PRE-
CIS domains and are shown in Table 1. Originally, RE-
AIM domains were not defined by a rating scale [23]. The
first scale was modeled after our first use of the PRECIS
rating scale that ranged from 0 to 4, where 0 represented
an extremely pragmatic study and 4 was extremely ex-
planatory. With subsequent uses of the RE-AIM do-
mains, the scale has been changed to remain identical to
the PRECIS scale where the smaller number represents
an extremely explanatory study and the larger number
represents an extremely pragmatic study.
The purpose of this article is to build on the work that
has been done on the use and applicability of the PRE-
CIS and RE-AIM frameworks by summarizing our ex-
perience applying these models to three studies that
have combined both frameworks to provide a more ro-
bust and comprehensive assessment of issues related to
Table 1 Summary of the Pragmatic Explanatory Continuum Indicator Summary (PRECIS) and the Reach, Effectiveness,
Adoption, Implementation, and Maintenance (RE-AIM) framework criteria
Framework Domain Criteria as described in published literature
PRECIS [16] Participant eligibility criteria Extremely pragmatic studies would enroll all participants who have the condition of interest
regardless of their responsiveness, past compliance, and co-morbidities.
Extremely explanatory studies would use a variety of exclusion criteria to identify those individuals
who would least likely respond to the intervention.
Experimental intervention
flexibility
Extremely pragmatic studies would leave the details of implementation of the experimental
condition up to the practitioner.
Extremely explanatory studies would have strict instructions for every intervention element (e.g.,
timing of intervention delivery, tactics used, educational materials used).
Experimental intervention
practitioner expertise
Extremely pragmatic studies would be conducted by individuals from a variety of backgrounds and
levels of experience and in a variety of settings.
Extremely explanatory studies would only be conducted by credentialed or seasoned
interventionists.
Comparison intervention Extremely pragmatic studies would use ‘usual care’ or available alternative interventions.
Extremely explanatory studies would use a placebo condition as the comparison group.
Comparison intervention
practitioner expertise
Extremely pragmatic studies would have the comparison intervention delivered by individuals with
full range of expertise levels, with only ordinary attention to training or experience.
Extremely explanatory studies would have the expertise of the comparison condition standardized
at a high level so as to be able to detect whatever comparative benefits the experimental
intervention might have.
Follow-up intensity Extremely pragmatic studies would not have formal follow-up visits. Instead administrative databases
would be used to assess outcomes.
Extremely explanatory studies would have formal follow-up visits on a prescribed schedule and
more extensive data collection than would occur in usual care or routine practice.
Primary trial outcome Extremely pragmatic studies would have a primary outcome that is objectively measured, has
clinical significance, and is one that can be assessed under usual conditions.
Extremely explanatory studies would have a primary outcome that is known to be a direct and
immediate relation to the intervention. The outcome may also require specialized training or testing
not normally used to determine outcome status.
Participant compliance with
prescribed intervention
Extremely pragmatic studies would have no measurement of compliance and no special strategies
to try to improve it.
Extremely explanatory studies would have study participants’ compliance monitored closely and
would have strategies to enhance compliance.
Practitioner adherence to
study protocol
Extremely pragmatic studies would have no measurement of practitioner adherence and no special
strategies to try to improve it.
Extremely explanatory studies would have close monitoring of how well the practitioners and study
sites are adhering to the study protocol.
Analysis of primary outcome Extremely pragmatic studies would include all participants in the analyses regardless of compliance
(e.g., intent-to-treat analysis).
Extremely explanatory studies would focus on analyses that allowed for estimating the maximum
benefit of the intervention (e.g., analysis restricted to those considered ‘completers’).
RE-AIM [23] Reach The absolute number, proportion, and representativeness of individuals who are willing to
participate in a given initiative, intervention, or program. Reporting of exclusion criteria and
percentage of potential participants excluded, Including the use of qualitative data to understand
recruitment.
Extremely pragmatic studies would include participants that are typical of those individuals with the
specified condition (including hard-to-reach individuals).
Extremely explanatory studies would include individuals who are not typical on most or all
characteristics of those with the specified condition.
Effectiveness The impact of the intervention on outcomes. Measure of primary outcome, including potential
negative effects, quality of life, and economic outcomes. Moderation analysis. Measure of short-term
attrition and use of qualitative data to understand outcomes.
Extremely pragmatic studies would have primary outcomes that are meaningful to patients and
providers. Explicit discussion of efforts to prevent harm to participants; report on unintended
harmful or beneficial consequences of the intervention.
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Table 1 Summary of the Pragmatic Explanatory Continuum Indicator Summary (PRECIS) and the Reach, Effectiveness,
Adoption, Implementation, and Maintenance (RE-AIM) framework criteria (Continued)
Extremely explanatory studies would have primary outcomes that are meaningful to investigators.
No efforts to capture unintended harmful or beneficial consequences of the intervention; only what
is necessary for IRB requirements.
Adoption The absolute number, proportion, and representativeness of settings and the individuals within
those settings who deliver the program who are willing to initiate a program. Reporting of setting
and staff exclusion criteria and percentage excluded. Use of qualitative data to understand settling
level adoption and staff participation.
Extremely pragmatic studies would have few or no setting exclusions. Sites are either randomly
selected or purposely selected for variation.
Extremely explanatory studies would have many exclusion criteria for settings and/or would try to
get the ‘best’ sites to participate.
Implementation Fidelity to study/program protocol and adaptations made to intervention during study/program.
Cost of intervention in terms of time and money. Consistency of implementation across staff, time,
setting, and subgroups – focus is on process. Use of qualitative data to understand implementation.
Extremely pragmatic studies would provide detailed reporting of modifications made and rationale.
Explicit discussion of efforts to contain costs and to make the intervention feasible for low resource
settings would also be included.
Extremely explanatory studies would have no mention of modifications to protocols or measures.
No effort to contain costs; uses state of the art resources and procedures.
Maintenance The extent to which a program or policy becomes institutionalized or part of the routine
organizational practices and policies. If and how the program/policy was adapted long-term. Some
measure/discussion of alignment to organization mission or sustainability of business model. Use of
qualitative data to understand setting level institutionalization.
Within the RE-AIM framework, maintenance also applies at the individual level. At the individual
level, maintenance has been defined as the long-term effects of a program on outcomes 6 or more
months after the most recent intervention contact. Measure of long-term attrition and differential
rates by patient characteristics and/or treatment condition. Use of qualitative data to understand
long-term effects.
Extremely pragmatic studies would focus on explicit plans for handing off intervention to setting/
site for continuation of the program/intervention after the completion of the study.
Extremely explanatory studies would not have a report of efforts to continue the intervention after
completion of the study.
Note: PRECIS ratings were originally done on a hub and spoke visual diagram with no numerical anchors on the lines representing each domain along the
pragmatic-explanatory continuum. The three exemplar studies used a numerical rating for each domain; one study used a scale of 1 to 5 (1 = explanatory and
5 = pragmatic) and the other two used a scale of 0 to 4 (where 0 = pragmatic and 4 = explanatory in one and 0 = explanatory and 4 = pragmatic in the other). As
for the RE-AIM ratings, RE-AIM domains were originally not defined by a rating scale. The three studies used a numerical scale for each domain that was identical
to the PRECIS rating scales for each study respectively.
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ences of using both PRECIS and RE-AIM frameworks in
three different studies. Thereafter, we summarize lessons
learned using the combined criteria and make recom-
mendations for future use. We conclude with a discus-
sion on implications for the broader issue of designing
and reporting results for studies intended to promote
translation into policy and practice.
Methods
Description of studies to illustrate use of the frameworks
The following three studies illustrate our experiences
applying both PRECIS and RE-AIM frameworks. These
three studies were selected because they are the only
studies to our knowledge that have combined both frame-
works, we have access to the data, and they illustrate dif-
ferent applications (e.g., planning, use to describe differentinterventions in a collaborative project and to conduct a
literature review).
The Practice-Based Opportunities for Weight Reduc-
tion (POWER) Trials Collaborative Research Group in-
cluded three individual studies funded by the National
Heart Lung and Blood Institute (NHLBI) [19]. Although
the studies did not share a common intervention proto-
col, all three tested a primary care-based intervention to
reduce weight among obese primary care patients who
had at least one other cardiovascular disease risk factor
[27]. The POWER trials had common components to fa-
cilitate potential cross-site comparisons, but each proto-
col also incorporated distinct, trial-specific elements
including different interventions and different secondary
outcome measurements (see Table 2).
The second study was a systematic review of eHealth
cancer prevention and control intervention trials [28].
Table 2 Use of the Pragmatic Explanatory Continuum Indicator Summary (PRECIS) and the Reach, Effectiveness,




Review of eHealth cancer
prevention and control
intervention trials [27]
My Own Health Report (MOHR)
trial [30]
Setting The POWER trials Collaborative
Research Group tested weight loss
interventions in primary care
settings.
eHealth intervention trials that used
patient facing technologies
addressing all phases of the cancer
care continuum (i.e., prevention
through end of life care).
Ongoing, delayed cluster
randomized intervention trial in
primary care settings.
Sample Three individual studies
(approximately 1,100 participants)
aimed at reducing weight in primary
care patients who were obese and
had at least one other cardiovascular
disease risk factor.
113 grouped studies (149 total
papers) were reviewed.
One study (nine pairs of diverse
primary care practices matched on
practice type, practice ownership,
geographic region, electronic health

















Individual composite scores were
created for both sets of ratings -
PRECIS and REAIM.
For studies in which eHealth
intervention replaced practitioners
with no personal or phone contact,
‘not applicable’ ratings were applied
to relevant PRECIS domains on
practitioner expertise and
practitioner compliance to study
protocol.
Added patient engagement items to
RE-AIM domains.
For studies in which multiple
interventions were compared, the
most intensive intervention served as
the experimental arm and least




type of study and
stage of study
The utility of creating a composite
score for each of the evaluation
domains is questionable.
PRECIS and RE-AIM domains could
be productively and reliably applied
to a variety of eHealth studies.
However, for studies in which
eHealth interventions replaced
practitioners with no personal or
phone contact, deciding the best
way to rate (or not rate) these
domains was a challenge.
PRECIS domains prior to the start of
the trial confirmed the design
decisions aligned with the trial’s
stated pragmatic purpose.
Since results of the trials were not
available at the time of applying the
domains, one must wait to evaluate
the utility of the domains in terms of
the extent to which scores predict
eventual success of programs and
their adoption, implementation, and





Nine reviewers total—six involved in
one of the studies and three
independent reviewers not
associated with any part of the
POWER studies.
Three PhD level and four masters
level scientists were randomly paired
for study reviews from a
convenience sample.
Three PhD level scientists indirectly
involved in the project were selected
as convenience sample.
Most had Ph.D. or M.D. degrees and
at least moderate experience in
clinical trials.
Three had previous experience using
PRECIS.




Read article on the PRECIS domains
by Thorpe et al. [16] and reviewed
the slide presentation on PRECIS by
Sackett [33].
All reviewers read the article on
PRECIS domains by Thorpe et al. [16]
the RE-AIM original article by
Glasgow, et al., [22] and the slides on
PRECIS by Sackett [33].
Read article on PRECIS domains by
Thorpe et al. [16] and reviewed the
slides by Sackett [33].
RE-AIM training was integrated into
PRECIS training following discussion
of original PRECIS domains. No
Training sessions also served to
develop consensus on all domains.
Conducted a one one-hour meeting
to go over domains as a group and
instructions for scoring.
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Table 2 Use of the Pragmatic Explanatory Continuum Indicator Summary (PRECIS) and the Reach, Effectiveness,
Adoption, Implementation, and Maintenance (RE-AIM) Framework domains to evaluate three studies (Continued)
background materials provided on
RE-AIM.
The rating form was pilot-tested by
all reviewers and refined based on
the ratings of a sub-sample of four
papers, not included in the study.
After refinements and clarification of
rating process, another two papers
were assigned to the entire group.
Evaluation process Each reviewer read the centrally
available protocol materials on each
intervention.
Articles were identified and grouped
into studies if more than one article
per study. Reviewers were assigned
by study grouped papers.
Study protocol was independently
reviewed and scored by each
reviewer and a consensus meeting
was held to resolve any
discrepancies
Each reviewer read a background
description of each project that
appeared in Obesity and Weight
Management [26].
After assignments, each reviewer
conducted a brief web search of
publications within PubMed to
identify any relevant papers to the
main study paper.
Any questions the reviewer had
were answered by a contact person
at each site, not involved in the
ratings.
Each study was independently
reviewed and scored by each
reviewer and a consensus meeting
was held to resolve any
discrepancies among any ‘not
applicable’ ratings.Reviewers then independently rated
each of the three projects on the
PRECIS domains followed by rating
on RE-AIM domains.
Reliability procedures PRECIS domains - The overall kappa
inter-rater reliability on the composite
PRECIS score was r = 0.88. The
interclass correlation for individual
items was 0.72 and for averages 0.96.
Each study was rated by two
reviewers.
Percent agreement using both exact
and within one-point measures
RE-AIM domains- Inter-rater reliability
on the composite scale was r = 0.71.
The interclass correlations were 0.45
for single items and 0.83 for
averages.
Weighted percent agreement scores
were calculated for PRECIS and RE-
AIM domains.
Lessons learned from
training on use of
domains
Leave ample time for training.
Several conference calls were held
among reviewers to discuss and
attempt to specify precisely what
was meant by each dimension and
to develop and refine the rating
instruments and instructions.
Leave ample time for reviewers to
become familiar with the evaluation
domains. It may take multiple
sessions to arrive at consensus on
how to routinely apply the domains.
Domains can be used with relatively
little training to evaluate a study
protocol.
Applications of criteria should be
completed by independent
reviewers not associated with studies
being rated in addition to the
team members due to observed
differences in rating one’s
own project.
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‘the use of emerging information and communication
technology, especially the Internet, to improve or enable
health and health care’, [29] and included email, mobile
phone text or applications, interactive voice response,
automated and electronic programs, and computer tai-
lored print but excluded telemedicine targeted solely at
clinicians that did not have a patient or consumer facing
interface. It included 113 studies across the cancer
control continuum (i.e., primary prevention, screening,treatment/disease management, survivorship, and end-
of-life care) [30].
The third study is the My Own Health Report (MOHR)
trial whose primary purpose was to study clinical imple-
mentation of and patient experience with the use of an au-
tomated health risk assessment and feedback system to
help clinics focus on patient-centered care issues [31].
The MOHR trial used a paired, cluster randomized de-
layed intervention design with nine pairs of primary
care clinics. The trial combined elements of pragmatic
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mixed methods approaches with practical outcome mea-
sures [33]. Research teams identified and selected matched
clinics that were similar in type (e.g., federally qualified
health center, practice based research network, family
practice, or internal medicine), and clinical characteris-
tics including geographic region, approximate size and
level of electronic health record integration. One clinic
in each pair was randomized to early implementation
while the second clinic was assigned to the delayed imple-
mentation condition.
Training on use of the domains
The three evaluations were conducted during different
phases of the research process. For the POWER study,
evaluation occurred during the implementation phase of
the project. The eHealth evaluation was conducted after
study completion as the review consisted solely of pub-
lished literature, and the MOHR evaluation was con-
ducted in the planning phase. A variety of reviewers
were used in the three different evaluation exercises as
described in Table 2. In the POWER trial, reviewers fa-
miliar and not familiar with the research protocols being
evaluated were used. In eHealth, one reviewer was the
lead investigator for one of the included studies. How-
ever, he was not assigned to review the study. None of
the other reviewers were associated with any of the pub-
lished works included in the review. In the MOHR trial,
individuals indirectly associated with the study were
used as reviewers. In all three cases, individuals were
highly educated and trained in the research process as
described below and in Table 2.
While the training process for the reviewers varied
across each evaluation, all began in a similar fashion
with reviewers studying the original PRECIS article [16]
and the PowerPoint presentation by Dr. Sackett [34],
and having two or more group meetings to discuss ap-
plication of the rating criteria. The POWER study was
our first use of the PRECIS framework. After review and
discussions on applying the PRECIS domains to the
POWER protocols, it was evident that additional domains
were necessary to capture key contextual factors for trans-
lation. Thus the additional domains from the RE-AIM
framework were added. Reviewers then re-assessed each
of the protocols with the additional RE-AIM domains.
The eHealth study had reviewers not familiar with the RE-
AIM framework read the original RE-AIM article [23] in
addition to reviewing the PRECIS training materials. Mul-
tiple training sessions were held to develop consensus on
both frameworks among raters on all domains. The rating
form that included both sets of evaluation criteria was
piloted and refined based on the ratings of a subsample of
four papers by all reviewers. After refinements and clarifi-
cation of the rating process, all reviewers evaluated twoadditional papers to pilot the revised criteria. The MOHR
study conducted a one-hour training session to review the
criteria as a group and instructions for using the criteria.
Use of the domains
All three projects were rated on a 5-point Likert-type scale
for the PRECIS and RE-AIM domains. The POWER study
used the original 0 – 4 scale, as described in the Sackett
presentation, where 0 was extremely pragmatic and 4 was
extremely explanatory. However, the eHealth study used a
1 – 5 rating scale, as described in Koppenaal, et al. [20],
and the MOHR study used a 0 – 4 scale, both such that
the lower score, the more explanatory the trial and the
higher the score, the more pragmatic the trial. In addition,
the POWER and eHealth studies created composite scores
for both PRECIS and RE-AIM domains.
In the POWER study, reviewers independently rated
each of the three protocols on all PRECIS and RE-AIM
domains using a paper rating form. In the eHealth study,
two reviewers were randomly assigned to each study and
reviewers rated approximately 38 studies each. All rating
information for each study was collected via a web-based
form in Survey Monkey. In the MOHR trial, reviewers
rated the study protocol using a paper rating form.
Different approaches to inter-rater reliability were used
because the three different studies had vastly different
designs, strategies for allocating reviewers, number of re-
viewers, and number of studies rated per reviewer. There-
fore, the approaches to assessing inter-rater reliability
differed as well. For POWER, intraclass correlation coeffi-
cients were calculated for individual items and an overall
kappa was calculated for each of the composite scores
[19]. In the eHealth review, weighted percent agreement
scores for PRECIS and RE-AIM domains were calculated
[28]. For the MOHR study, percent agreement score for
each PRECIS and RE-AIM domain was calculated using a
standard of exact agreement [31].
Results
Experiences using PRECIS and RE-AIM to evaluate three
different studies
The POWER trial was our first experience using PRECIS
and the first numerical rating using RE-AIM domains.
Although the PRECIS article examples and the presenta-
tion were useful background, there were several issues
that were unclear to some reviewers, and we found it ne-
cessary to add explicit anchors for the ratings and to rate
and discuss example studies not part of the formal
evaluation. We also identified one person from each of
the three POWER research centers very familiar with
that center’s protocol, not a reviewer (e.g., a program
manager) who was available to answer any questions
and clarify issues that were unclear to reviewers from
the study protocols.
Table 3 Average ratings (standard deviation) on PRECIS







Participant Eligibility Criteria 1.8 (0.6) 3.2 (0.7) 3.0 (0)
Experimental Intervention
Flexibility
1.6 (0.9) 2.8 (0.9) 4.0 (0)
Practitioner Expertise
(Experimental)
1.6 (0.9) 2.7 (0.9) 3.3 (0.6)
Comparison Intervention
Flexibility
2.9 (1.2) 2.9 (1.2) 4.0 (0)
Practitioner Expertise
(Comparison)
2.5 (1.3) 2.8 (1.0) 4.0 (0)
Follow-up Intensity 1.4 (1.1) 3.2 (0.9) 3.0 (0)
Primary Trial Outcome 2.4 (0.7) 2.9 (0.7) 3.3 (0.6)
Participant Compliance 1.2 (0.8) 3.2 (0.8) 2.7 (0.6)
Practitioner Adherence
to Protocol
1.7 (0.9) 3.6 (1.0) 3.3 (0.6)
Analysis of Primary Outcome 2.0 (1.4) 3.5 (0.8) 3.3 (0.6)
Participant Representativeness 2.3 (0.8) 2.5 (0.7) 3.3 (0.6)
Setting Representativeness 2.1 (1.3) 2.8 (1.0) 3.0 (0)
Adaptation/Change 1.4 (1.0) 1.5 (0.6) 3.7 (0.6)
Sustainability 1.4 (1.0) 1.6 (0.7) 2.0 (0)
Costs/Feasibility of Treatment 2.0 (1.2) 1.6 (0.7) 4.0 (0)
Note: PRECIS: Pragmatic Explanatory Continuum Indicator Summary. RE-AIM:
Reach, Effectiveness, Adoption, Implementation, and Maintenance Framework.
POWER Trials = Practice-Based Opportunities for Weight Reduction Trials
Collaborative Research Group; eHealth Reviews = Systematic Review of eHealth
Cancer Prevention and Control Interventions; MOHR =My Own Health Report.
To make ratings comparable, the ratings were converted so that for all studies,
scoring continuum: 1 = Explanatory, 5 = Pragmatic.
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intervention trials was the first published article using
PRECIS and RE-AIM to evaluate eHealth intervention
(EHI) studies. Several unanticipated issues were unique
to applying such domains to EHI studies. For studies in
which EHI replaced practitioners with no personal or
phone contact, ‘not applicable’ ratings were applied to
relevant PRECIS domains on practitioner expertise and
practitioner compliance to study protocol. Any discrep-
ancies in ‘not applicable’ ratings between reviewers were
identified and discussed for consensus during the data
cleaning process. Additionally, reviewers had to discuss
and agree upon assignment of experimental and control
interventions for studies in which multiple interventions
were compared. For these studies, the most intensive
intervention served as the experimental arm and the
least intensive intervention served as the control arm.
We also found that few studies reported on factors re-
lated to cost and setting representativeness relevant to
the RE-AIM domains and therefore, could not rate such
aspects of the individual studies.
Because the MOHR study only used three reviewers for
one protocol that they were already familiar with, there
were far fewer issues in terms of training and rating.
However, the reviewers did feel that the RE-AIM domains
did not capture one factor they felt was important to
generalizability, patient engagement. As such, this domain
was added and rated. The reviewers tended to rate some
aspects of the protocol highly with regard to pragmatism
and generalizability. However, this was not consistent
across specific domains and consensus discussions seemed
to resolve any bias towards these responses.
Lessons learned using PRECIS and RE-AIM frameworks
These three diverse applications illustrate that both the
PRECIS and RE-AIM frameworks can be used for di-
verse purposes and across diverse content areas and
types of studies. The following lessons can be taken from
this experience. First, although the domains can be reli-
ably coded by a variety of research staff after a short
training activity, time should be dedicated to discussions
about precise definitions for each domain and practice
using the criteria (see Table 2). Second, reviewers in all
studies found that the RE-AIM domains in combination
with the PRECIS domains addressed important add-
itional information related to pragmatic research. Both
sets of domains can reveal meaningful differences across
studies and across domains within a study. The most con-
sistent and largest differences across studies were that
studies were less pragmatic on the RE-AIM domains than
on the original PRECIS domains (see Table 3). In particu-
lar, adaption, sustainability, and costs were seldom re-
ported. It is both sobering and ironic that these types of
issues are precisely the ones about which stakeholdersmost need information to consider adoption and replica-
tion of an intervention program [3]. Third, two of the
three evaluations had reviewers who were directly or
somewhat directly related to the study being evaluated. It
was observed that reviewers directly involved with a study
tended to rate their own study as more pragmatic than
others. Having reviewers who are both familiar and un-
familiar with an intervention or program could help
minimize, or control for, this finding. Fourth, given the na-
ture of eHealth interventions, reliance on technology as
the intervention delivery mechanism, the role of the prac-
titioner (i.e., practitioner expertise and adherence in PRE-
CIS) was not applicable to many of the self-administered
intervention studies. The impact of not scoring these two
PRECIS domains is unclear and thus warrants further
discussion on how to best incorporate or properly rate do-
mains when used with eHealth and other automated inter-
vention studies.
Fifth, given the PRECIS and RE-AIM domains focus
on trials that have explicit experimental and control arms,
reviewers had to designate study arms as experimental or
control in research that compared three or more interven-
tions. This is likely to present similar challenges to research
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ness research, adaptive design interventions, or multi-
component intervention trials. Sixth, there was difference
of opinion regarding the value of calculating a summary
score for both PRECIS and RE-AIM domains. Calculating
such a score can be helpful but also potentially misleading.
The summary score can give a sense as to where a study
falls on the pragmatic-explanatory continuum as whole,
but it masks the diversity of the individual domains. For
example, two studies could have an identical overall PRE-
CIS summary score. However, one study might have been
much more explanatory in terms of eligibility criteria for
trial participants and the other trial much more pragmatic
on this domain. It is recommended that when overall sum-
mary scores are used, individual domains should also be
reported to identify how results on different domains con-
tribute to the overall score and to be able to assess how
each domain aligns with the purpose of the study.
Discussion
An increasing number of programs and studies claim to
be pragmatic. Use of both PRECIS and RE-AIM frame-
works can be used to demonstrate specifically where and
how an individual study, or group of studies, is and is not
pragmatic. Comparing ratings of domains within the same
study allows for understanding the pragmatic versus ex-
planatory design elements of the trial. Whereas compar-
ing domain ratings across trials allows clinicians, policy
makers, and study reviewers to compare across studies
to make meaningful judgments about which intervention
has generalizability and applicability to their population(s)
of interest and the level of reasonable effectiveness that
can be expected in different contextual settings versus
those in explanatory trials.
Several evaluation frameworks have been developed to
facilitate translation of research findings. However, many
are designed solely for evaluation [35]. Combining both
PRECIS and RE-AIM allows for standard reporting of
both development and evaluation over the life course of
a study. In the planning phase of a study, PRECIS allows
for assessing the match between the trial design and the
research and RE-AIM can be used to provide greater de-
tail relative to some PRECIS domains (e.g., description of
eligibility criteria and calculation of reach), and also to
address other issues not in PRECIS important to potential
adopting settings (e.g., costs required, representativeness
of settings). RE-AIM can be used across the entire span of
the study to understand the why behind success or failure
of a study by describing the context in which the study oc-
curred [36]. PRECIS can be used periodically throughout
the study and at study conclusion to assess how adapta-
tions and changes made over the course of the study im-
pact the design and whether the end result still aligned
with the original purpose of the study, respectively.There is considerable benefit to using both frame-
works to assess key components necessary for designing
and reporting results for studies intended to promote
translation of research into practice and policy. However,
there are still many questions that need to be explored
as use of both frameworks increases. First, what is the
best rating scale to use? Is a 5-point Likert scale or some
other scale the best way to evaluate a study or should one
solely use a diagram without defined end-points? Is there
value to using a scale to assess each PRECIS and RE-AIM
domain or is a visual diagram sufficient? If a visual dia-
gram is sufficient, is the PRECIS ‘spoke and hub’ diagram
effective for also displaying the RE-AIM domains?
Second, use of some PRECIS domains to rate some
health services studies is currently problematic. For ex-
ample, in the eHealth review, there were studies that evalu-
ated automated interventions without involvement of
practitioners, with no personal or phone contact. ‘Not ap-
plicable’ ratings were applied to the PRECIS domains on
practitioner expertise and practitioner compliance to study
protocol (see Additional file 1). Is this the right way to
apply the domains or should it be given a score? Moreover,
usual care comparison conditions could be viewed as either
explanatory or pragmatic depending on the lens of the
evaluator. For example, how would participant compliance
be rated when a health educator meets with a patient
regarding self-management of diabetes and the educator
encourages the individual to problem solve concerning
self-monitoring their blood sugar levels and/or exercise
more frequently to reach their health goals? This is usual
care so could be viewed as extremely pragmatic in nature.
However, it could also be viewed as being explanatory as it
is encouraging patients to be more compliant. Thus, use of
RE-AIM in addition to PRECIS can help complete, or at
minimum, provide additional information to help under-
stand why PRECIS domains might be viewed as not rele-
vant or interpreted differently by two different evaluators.
Third, who should be a reviewer? There are pros and
cons to including reviewers who are intimately familiar
with a project versus those who are completely inde-
pendent. Although not investigated in these three stud-
ies, these domains could be used by both researchers
and stakeholders including patients and practitioners to
help collaboratively design pragmatic studies. Additional
studies are needed to determine if the finding that those
familiar with a study rate it as more pragmatic is a
generalizable phenomenon, as we observed in the rat-
ings of the MOHR study. If so, this would imply that fa-
miliarity with a study should be balanced across studies
to prevent potential bias.
Strengths and limitations
This evaluation only included three studies, and replica-
tion, especially in different content areas and types of
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cially those involved in team science [37] and commu-
nity engaged projects to use the PRECIS and RE-AIM
frameworks to increase collaboration and transparency,
as well as for program planning and adaptations. Also,
since the RE-AIM domains were developed to supple-
ment the PRECIS domains for each of the three applica-
tions reported, the specific RE-AIM domains varied
slightly across studies. The PRECIS domains are due to
be revised later in 2014 [22], and at that time, it may be
possible to also arrive at a common, standard set of ac-
companying RE-AIM domains, assuming they are still
needed to supplement PRECIS. Strengths of the paper
include the consistency of results and general usefulness
of these rating tools across three different content areas,
different phases of the research enterprise, and by differ-
ent types of reviewers.
Conclusion
The importance of pragmatic trials and dissemination and
implementation research to improve health and health
care delivery in the U.S. is gaining increased attention
[38,39]. Reporting on pragmatic rating criteria such as the
PRECIS and RE-AIM scales can increase transparency
and help reviewers and potential adoption settings make
more informed judgments about programs and their ap-
plicability to different settings and under different condi-
tions. However, because pragmatic research focuses on
real-world applications of interventions, understanding
the context in which it occurred is critical. Understanding
whether a study design aligns with one’s research question
in terms of being pragmatic versus explanatory should
not stand alone without an understanding of how the
context of participants, setting, and processes involved
affected the results. We encourage those planning and
evaluating health research interventions to use and re-
port on PRECIS and RE-AIM domains, and to contrib-
ute to their refinement.
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